Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R G Taylor

Showing results (231-240 of 259) with videos related to

Pageof 26
Sort By:
Circulation. Heart Failure|March 7, 2025
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated CardiomyopathyNatasha L Altman, Edward A Gill, Rami Kahwash, et al.
Heart Rhythm|May 10, 2023
Multicenter clinical and functional evidence reclassifies a recurrent noncanonical filamin C splice-altering variantMatthew J O'Neill, Suet Nee Chen, Lynne Rumping, et al.
Stem Cell Reports|February 26, 2021
Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic CardiomyopathyWalter E Knight, Yingqiong Cao, Ying-Hsi Lin, et al.
JACC. Clinical Electrophysiology|August 2, 2018
Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell-Cell Adhesion StructuresRene L Begay, Sharon L Graw, Gianfranco Sinagra, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Journal of the American College of Cardiology|May 8, 2024
Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular CardiomyopathiesMatteo Castrichini, Antonio De Luca, Giulia De Angelis, et al.
Circulation. Heart Failure|March 16, 2019
Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic CardiomyopathyVictoria N Parikh, Colleen Caleshu, Chloe Reuter, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
The New England Journal of Medicine|February 17, 2012
Truncations of titin causing dilated cardiomyopathyDaniel S Herman, Lien Lam, Matthew R G Taylor, et al.
Pageof 26

Showing results (231-240 of 259) with videos related to

Sort By:
Pageof 26
Circulation. Heart Failure|March 7, 2025
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated CardiomyopathyNatasha L Altman, Edward A Gill, Rami Kahwash, et al.
Heart Rhythm|May 10, 2023
Multicenter clinical and functional evidence reclassifies a recurrent noncanonical filamin C splice-altering variantMatthew J O'Neill, Suet Nee Chen, Lynne Rumping, et al.
Stem Cell Reports|February 26, 2021
Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic CardiomyopathyWalter E Knight, Yingqiong Cao, Ying-Hsi Lin, et al.
JACC. Clinical Electrophysiology|August 2, 2018
Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell-Cell Adhesion StructuresRene L Begay, Sharon L Graw, Gianfranco Sinagra, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Journal of the American College of Cardiology|May 8, 2024
Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular CardiomyopathiesMatteo Castrichini, Antonio De Luca, Giulia De Angelis, et al.
Circulation. Heart Failure|March 16, 2019
Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic CardiomyopathyVictoria N Parikh, Colleen Caleshu, Chloe Reuter, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
The New England Journal of Medicine|February 17, 2012
Truncations of titin causing dilated cardiomyopathyDaniel S Herman, Lien Lam, Matthew R G Taylor, et al.
Pageof 26